Shopping Cart 0
Cart Subtotal
USD 0

Aerie Pharmaceuticals Inc (AERI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with glaucoma and other diseases of the eye. The company's product candidates comprise rhopressa, a once-daily eye drop which is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence in the US and Ireland. Aerie is headquartered in Irvine, California, the US.

Aerie Pharmaceuticals Inc (AERI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12

Venture Financing 13

Aerie Pharma Raises Additional USD12 Million in Venture Financing 13

Aerie Pharma Raises USD 3 Million In Venture Financing 14

Partnerships 15

ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15

Aerie Pharma Enters into R&D Agreement with Royal DSM 16

Licensing Agreements 17

Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17

Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18

Aerie Pharma Enters into Licensing Agreement with GrayBug 19

Equity Offering 20

Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20

Aerie Pharma Raises USD75 Million in Public Offering of Shares 22

Aerie Pharma Raises USD75 Million in Public Offering of Shares 24

Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26

Aerie Pharma Completes IPO For USD 77.3 Million 27

Debt Offering 29

Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29

Aerie Pharmaceuticals Inc-Key Competitors 31

Aerie Pharmaceuticals Inc-Key Employees 32

Aerie Pharmaceuticals Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 35

Strategy And Business Planning 35

Oct 23, 2018: Aerie Pharmaceuticals establishes GMP PRINT production facility in an expanded global headquarters 35

Financial Announcements 36

Nov 06, 2018: Aerie Pharmaceuticals reports third quarter 2018 financial results and provides business update 36

Aug 08, 2018: Aerie Pharmaceuticals reports second quarter 2018 financial results and provides business update 38

May 08, 2018: Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update 39

Feb 28, 2018: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance 40

Nov 08, 2017: Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 42

Aug 01, 2017: Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 43

May 02, 2017: Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 44

Mar 07, 2017: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 45

Corporate Communications 46

Sep 12, 2018: Aerie Pharmaceuticals names David W. Gryska as Board Director 46

Dec 04, 2017: Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region 47

Aug 28, 2017: Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director 48

Apr 24, 2017: Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance 49

Apr 10, 2017: Aerie Pharmaceuticals Announces Expansion of Commercialization Team 50

Product News 51

12/18/2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension 51

08/15/2018: Aerie Pharmaceuticals Reports Topline Result from Rhopressa Mechanism of Action Study 52

05/03/2017: Envisia Therapeutics Announces New Data On ENV1105 At ASCRS 2017 Annual Meeting 53

04/30/2018: Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa (netarsudil ophthalmic solution) 0.02% 54

Feb 21, 2018: New glaucoma drugs yield large, lasting reductions in intraocular pressure 55

Product Approvals 56

Oct 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa (netarsudil ophthalmic solution) 0.02% 56

Sep 20, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa (netarsudil ophthalmic solution) 0.02% 57

Aug 08, 2017: Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer 58

May 15, 2017: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02% 59

Mar 01, 2017: Aerie Pharmaceuticals Announces Resubmission of NDA for Rhopressa (netarsudil ophthalmic solution) 0.02% 60

Clinical Trials 61

Oct 09, 2018: Aerie Pharmaceuticals Announces Drug Application for Regulatory Approval Accepted for Review in Europe 61

Nov 16, 2017: Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan 62

Apr 12, 2017: Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02% 63

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aerie Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12

Aerie Pharma Raises Additional USD12 Million in Venture Financing 13

Aerie Pharma Raises USD 3 Million In Venture Financing 14

ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15

Aerie Pharma Enters into R&D Agreement with Royal DSM 16

Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17

Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18

Aerie Pharma Enters into Licensing Agreement with GrayBug 19

Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20

Aerie Pharma Raises USD75 Million in Public Offering of Shares 22

Aerie Pharma Raises USD75 Million in Public Offering of Shares 24

Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26

Aerie Pharma Completes IPO For USD 77.3 Million 27

Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29

Aerie Pharmaceuticals Inc, Key Competitors 31

Aerie Pharmaceuticals Inc, Key Employees 32

Aerie Pharmaceuticals Inc, Other Locations 34

Aerie Pharmaceuticals Inc, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aerie Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with glaucoma and other diseases of the eye. The company's product candidates comprise rhopressa, a once-daily eye drop which is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence in the US and Ireland. Aerie is headquartered in Irvine, California, the US.

Aerie Pharmaceuticals Inc (AERI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12

Venture Financing 13

Aerie Pharma Raises Additional USD12 Million in Venture Financing 13

Aerie Pharma Raises USD 3 Million In Venture Financing 14

Partnerships 15

ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15

Aerie Pharma Enters into R&D Agreement with Royal DSM 16

Licensing Agreements 17

Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17

Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18

Aerie Pharma Enters into Licensing Agreement with GrayBug 19

Equity Offering 20

Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20

Aerie Pharma Raises USD75 Million in Public Offering of Shares 22

Aerie Pharma Raises USD75 Million in Public Offering of Shares 24

Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26

Aerie Pharma Completes IPO For USD 77.3 Million 27

Debt Offering 29

Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29

Aerie Pharmaceuticals Inc-Key Competitors 31

Aerie Pharmaceuticals Inc-Key Employees 32

Aerie Pharmaceuticals Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 35

Strategy And Business Planning 35

Oct 23, 2018: Aerie Pharmaceuticals establishes GMP PRINT production facility in an expanded global headquarters 35

Financial Announcements 36

Nov 06, 2018: Aerie Pharmaceuticals reports third quarter 2018 financial results and provides business update 36

Aug 08, 2018: Aerie Pharmaceuticals reports second quarter 2018 financial results and provides business update 38

May 08, 2018: Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update 39

Feb 28, 2018: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance 40

Nov 08, 2017: Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 42

Aug 01, 2017: Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 43

May 02, 2017: Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 44

Mar 07, 2017: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 45

Corporate Communications 46

Sep 12, 2018: Aerie Pharmaceuticals names David W. Gryska as Board Director 46

Dec 04, 2017: Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region 47

Aug 28, 2017: Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director 48

Apr 24, 2017: Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance 49

Apr 10, 2017: Aerie Pharmaceuticals Announces Expansion of Commercialization Team 50

Product News 51

12/18/2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension 51

08/15/2018: Aerie Pharmaceuticals Reports Topline Result from Rhopressa Mechanism of Action Study 52

05/03/2017: Envisia Therapeutics Announces New Data On ENV1105 At ASCRS 2017 Annual Meeting 53

04/30/2018: Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa (netarsudil ophthalmic solution) 0.02% 54

Feb 21, 2018: New glaucoma drugs yield large, lasting reductions in intraocular pressure 55

Product Approvals 56

Oct 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa (netarsudil ophthalmic solution) 0.02% 56

Sep 20, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa (netarsudil ophthalmic solution) 0.02% 57

Aug 08, 2017: Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer 58

May 15, 2017: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02% 59

Mar 01, 2017: Aerie Pharmaceuticals Announces Resubmission of NDA for Rhopressa (netarsudil ophthalmic solution) 0.02% 60

Clinical Trials 61

Oct 09, 2018: Aerie Pharmaceuticals Announces Drug Application for Regulatory Approval Accepted for Review in Europe 61

Nov 16, 2017: Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan 62

Apr 12, 2017: Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02% 63

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aerie Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aerie Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aerie Pharma Acquires Rights of PRINT Technology and Other Assets from Envisia Therapeutics 12

Aerie Pharma Raises Additional USD12 Million in Venture Financing 13

Aerie Pharma Raises USD 3 Million In Venture Financing 14

ViSci Enters Into Option Agreement with Novaer to License Eye-D Technology 15

Aerie Pharma Enters into R&D Agreement with Royal DSM 16

Aerie Pharma Expands Licensing Agreement with DSM Biomedical 17

Aerie Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 18

Aerie Pharma Enters into Licensing Agreement with GrayBug 19

Aerie Pharma Raises USD74.3 Million in Public Offering of Shares 20

Aerie Pharma Raises USD75 Million in Public Offering of Shares 22

Aerie Pharma Raises USD75 Million in Public Offering of Shares 24

Aerie Pharma Plans Public Offering of Shares for up to USD50 Million 26

Aerie Pharma Completes IPO For USD 77.3 Million 27

Aerie Pharma Raises USD125 Million in Private Placement of 1.75% Notes Due 2021 29

Aerie Pharmaceuticals Inc, Key Competitors 31

Aerie Pharmaceuticals Inc, Key Employees 32

Aerie Pharmaceuticals Inc, Other Locations 34

Aerie Pharmaceuticals Inc, Subsidiaries 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aerie Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.